Immupharma (IMM)

 

Latest News

London Investor Evening

RNS Number: 9140E Immupharma PLC 15 February 2018 15 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") London Investor Evening Monday 26 February 2018 @ 6pm ImmuPharma PLC (LSE: IMM) , specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an invest...

Holding(s) in Company

RNS Number: 4832E Immupharma PLC 09 February 2018 9 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Holding in Company ImmuPharma PLC (LSE: IMM) , the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Com...

Holding(s) in Company

RNS Number: 1713E Immupharma PLC 07 February 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma p...

Holding(s) in Company

RNS Number: 8539D Immupharma PLC 05 February 2018 5 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Notification of Major Interest Lanstead Increases Holding to over 5% ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, has received notification that Lanstead Capital LP ("Lanstead") has confir...

All News

DateHeadlineSource
01-07-16Holding(s) in CompanyRNS
27-06-16Second Price Monitoring ExtnRNS
27-06-16Price Monitoring ExtensionRNS
20-06-16ImmuPharma appoints joint broker StockMarketWire
20-06-16Appointment of Joint BrokerRNS
09-06-16Why are Immupharma plc, Purplebricks Group plc and Roxi Petroleum plc among today’s major movers?Motley Fool
09-06-16Holding(s) in CompanyRNS
08-06-16Symposium with Lupuzors Inventor Prof. S MullerRNS
07-06-16ImmuPharma update on Lupuzor studyStockMarketWire
07-06-16Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?Motley Fool
07-06-16European Patients Commence Dosing in LupuzorRNS
02-06-16Director/PDMR ShareholdingRNS
31-05-16Holding(s) in CompanyRNS
26-05-16ImmuPharma resolutions passed at AGMStockMarketWire
26-05-16Result of AGMRNS
25-05-16Holding(s) in CompanyRNS
04-05-16ImmuPharma losses widenStockMarketWire
04-05-16Annual Financial Report & Notice of AGMRNS
04-05-16Final ResultsRNS
26-04-16ImmuPharma schedules FY results StockMarketWire
26-04-16Notice of ResultsRNS
22-04-16Holding(s) in CompanyRNS
09-03-16ImmuPharma starts European patient recruitment for Lupuzor trial StockMarketWire
09-03-16First European Site Opens - Patient RecruitmentRNS
08-03-16Holding(s) in CompanyRNS
07-03-16Holding(s) in CompanyRNS
01-03-16EIS and VCT Qualifying Status and Issue of EquityRNS
29-02-16Holding(s) in CompanyRNS
24-02-16ImmuPharma raises GBP7.7mStockMarketWire
24-02-16Issue of EquityRNS
22-02-16ImmuPharma fundraising approved StockMarketWire
22-02-16Result of GMRNS
15-02-16Dosing starts for ImmuPharma's Lupuzor trial StockMarketWire
15-02-16US PATIENTS COMMENCE DOSING IN PHASE III STUDYRNS
05-02-16ImmuPharma raises GBP8.3m via placingStockMarketWire
05-02-16Placing and Subscription Raises £8.3 millionRNS
05-02-16ImmuPharma fundraising to finance Lupuzor trial StockMarketWire
05-02-16Proposed Placing and SubscriptionRNS
21-01-16Holding(s) in CompanyRNS
15-12-15ImmuPharma update on Lupuzor StockMarketWire

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account